These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 17262193

  • 1. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan.
    Vela-Ojeda J, García-Ruiz-Esparza MA, Padilla-González Y, Gómez-Almaguer D, Gutiérrez-Aguirre CH, Gómez-Rangel D, Morales-Toquero A, Ruiz-Delgado GJ, Delgado-Lamas JL, Ruiz-Argüelles GJ.
    Ann Hematol; 2007 Apr; 86(4):277-82. PubMed ID: 17262193
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L, Raju GM, Ganessan K, Shawgi S, Menon H, Wadhwa J, Sharma A, Singh R, Kochupillai V.
    Natl Med J India; 2003 Apr; 16(1):16-21. PubMed ID: 12715951
    [Abstract] [Full Text] [Related]

  • 4. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
    O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, Naresh K, Lampert I, Samson D, Narat S, Kanfer E, Olavarria E, Apperley JF, Rahemtulla A.
    Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
    [Abstract] [Full Text] [Related]

  • 5. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
    Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P.
    Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma.
    Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J.
    Bone Marrow Transplant; 2002 Nov; 30(10):673-9. PubMed ID: 12420206
    [Abstract] [Full Text] [Related]

  • 9. High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
    Torjman L, Ladeb S, Lakhal A, Ben Othman T, Abdelkefi A, Ben Abdeladhim A.
    Tunis Med; 2007 Jan; 85(1):35-8. PubMed ID: 17424707
    [Abstract] [Full Text] [Related]

  • 10. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
    Sharma A, Lokeshwar N, Raina V, Mohanti BK, Kumar R.
    Natl Med J India; 2007 Jan; 20(3):121-4. PubMed ID: 17867615
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
    Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E, Belanger C, Janvier M, Chevret S, Brouet JC, Ravaud P, Group Myelome-Autogreffe.
    J Clin Oncol; 2005 Dec 20; 23(36):9227-33. PubMed ID: 16275936
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
    Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R, Breitz H, Alexanian R, Champlin R, Giralt S.
    Biol Blood Marrow Transplant; 2007 May 20; 13(5):543-9. PubMed ID: 17448913
    [Abstract] [Full Text] [Related]

  • 19. The first 2 years of clinical experience with peripheral blood stem cell transplantation for various hematological malignancies: results from a single Baskent University Center.
    Ozdogu H, Boga C, Kizilkilic E, Kozanoglu I, Karakus S, Sahin FI, Unalan D, Haberal M.
    Transplant Proc; 2007 May 20; 39(4):1257-60. PubMed ID: 17524948
    [Abstract] [Full Text] [Related]

  • 20. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
    Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F, Falco P, Boccadoro M.
    Eur J Haematol; 2006 Apr 20; 76(4):273-7. PubMed ID: 16519697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.